EN | TR
E-ISSN: 3061-9947
Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status
PDF
Cite
Share
Request
Original Article
VOLUME: 55 ISSUE: 2
P: 103-108
2022

Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status

Acta Haematol Oncol Turc 2022;55(2):103-108
DOI: 10.5505/aot.2022.13008
Utku Iltar 1
Ozan Salim 1
Turgay Ulaş 2
Sibel Berker Karaüzüm 3
Çiğdem Aydin 4
Levent Undar 1
1. Akdeniz University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Antalya
2. Near East University School of Medicine, Department of Internal Medicine, Division of Hematology, Nicosia/Cyprus
3. Akdeniz University School of Medicine, Department of Medical Biology and Genetics, Antalya
4. Mehmet Akif Ersoy University, Bucak School of Health, Department of Nursing, Burdur
5.
No information available.
No information available
Received Date: 2022-01-12T11:18:22
Accepted Date: 2022-08-01T05:54:31
PDF
Cite
Share
Request

Abstract

INTRODUCTION

The aim of the study was to evaluate the relationship between CD23 expression status and clinical features in multiple myeloma patients.

METHODS

We retrospectively analyzed the data of 196 patients diagnosed with multiple myeloma in our institution between May 2010 and August 2018.

RESULTS

Compared to the CD23 negative group, in the CD23 positive group, the incidence of anemia was significantly lower, and the incidence of CD20 expression and the rate of R-ISS stage 1 patients was significantly higher. No similar association was found between R-ISS and other cell surface markers

DISCUSSION AND CONCLUSION

In conclusion, clinical presentations of multiple myeloma patients with aberrant CD23 expression show some clinical differences from those without. The fact that MM patients with CD23 expression were clustered in the favorable prognostic group according to R-ISS drew attention to its prognostic value. For MM patients, the addition of CD23 to the routine flow cytometry panel may be considered. In this respect, examination of CD23 expression is required in a larger group of cases to assess its prognostic value in MM.